Hrt Financial LP Aurinia Pharmaceuticals Inc. Transaction History

Hrt Financial LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	SELL	$7.13 - $9.49 $26,915 - $35,824	-3,775 Reduced 10.93%	30,761 $276,000
Q3 2023 Nov 13, 2023	SELL	$7.77 - $12.27 $549,237 - $867,329	-70,687 Reduced 67.18%	34,536 $268,000
Q2 2023 Aug 11, 2023	BUY	$8.96 - $11.69 $135,815 - $177,197	15,158 Added 16.83%	105,223 $1.02 Million
Q1 2023 May 12, 2023	BUY	$5.94 - $11.27 $534,986 - $1.02 Million	90,065 New	90,065 $987,000
Q2 2022 Aug 12, 2022	SELL	$8.95 - $12.8 $346,857 - $496,064	-38,755 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$10.05 - $22.48 $389,487 - $871,212	38,755 New	38,755 $479,000
Q3 2021 Nov 15, 2021	SELL	$10.93 - $23.55 $1.06 Million - $2.28 Million	-96,892 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$10.0 - $14.52 $968,920 - $1.41 Million	96,892 New	96,892 $1.26 Million

209

58.7M

1.14M

1.51M

Ticker AUPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 141,892,000
Market Cap $1.15B
Description
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license...

Get notified when there are updates to the investment portfolio of Hrt Financial LP, based on Form 13F filings with the SEC.

Stay updated on Hrt Financial LP with notifications on news.